Sounds reasonable to me. Thanks. I guess the athletic benefits will probably not work out. I have high hopes for nextact and I'd like to point out we aren't simply talking about APRI having only Vitaros and Femprox. Those are just the first and most likely to generate revenue. There could be many more after that. I wonder what APRI will be working on five years from now, assuming Vitaros and Femprox succeed of course. If Vitaros establishes a strong market presence you can bet that other pharmas will be beating down the door to lock down some rights to other potential drug combinations with nextACT and whatever version of DDAIP is out.
News 
Market Data 
Discover 
AI
